SAN DIEGO, CA – Medical Marijuana, Inc. (OTC PINK: MJNA) announced today that its portfolio company Kannalife Sciences, Inc. (“Kannalife”) was the focus of a Sports Illustrated online article about how the breakthrough cannabinoid research the Company is conducting could be the “future new wave of medicine” for traumatic brain injuries. The article also highlights the potential benefits of Cannabidiol (CBD) treatment for NFL players.
The July 13 SI.com article titled, “How cannabis is helping one company research treatment of CTE,” describes how bio-pharmaceutical and phyto-medical company Kannalife’s study of the cannabis plant and its chemical constituents for therapeutic value could “change the landscape of how brain injuries of all varieties from CTE to Alzheimer’s and Parkinson’s — will eventually be treated.” The article also discusses how non-performance-altering and non-psychoactive CBD could benefit NFL players and how one ex-NFL player in particular used marijuana to curb his addiction to pain killers after rehabilitating himself at https://firststepbh.com/blog/quitting-drugs-cold-turkey-doesnt-work/.
“What will it take for us to work with the NFL?” Kannalife CEO Dean Petkanas asks in the article. “A phone call. That’s it.”
Kannalife co-founder Thoma Kikis says in the article that Kannalife is “pushing the boundaries on this whole industry,” referring to the burgeoning medical marijuana market. “We think this is going to be the new wave of medicine,” he added.
“The fact that national press, such as Sports Illustrated, is open to covering the NFL and reporting on players using marijuana to control pain and assist in injury repair/inflammation, shows responsibility and fair reporting practices,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We’re thankful that this leading sports website is bringing light and awareness to how Cannabis, including both THC and CBD, could be a leading therapeutic approach for treating a potential wide variety of ailments as a result of years of aggressive, hard-contact injuries. Certainly the neuroprotective benefits are well researched and a dual-pronged approach to the head injury situation seems appropriate. Ideally, a botanical neuroprotective/preventative formula may hold benefit for at-risk-of-concussion individuals — but certainly Kannalife’s new molecule for those who have suffered head/brain trauma may provide new and exciting options for the neurological community. For ex-athletes and other with head injury / trauma, please know that our team is hard at work toward providing solutions that will please the medical community’s exacting standards.”
Dr. Titus continued: “Medical marijuana as a potentially healthier and more viable alternative to treating players’ pain-related issues — rather than with addictive opioid painkillers — is a major step toward a new overall and comprehensive approach to pain therapy. If we can simultaneously demonstrate that botanical remedies are supporting the largest self-regulatory system within the human body, the endogenous cannabinoid system (with cannabis and cannabis/hemp CBD products) then science will have greater support for the anecdotal testimony of many of these great athletes (and others) who deal with pain on a continual basis. Certainly these news organizations are helping our industry-wide efforts to change the way we all think about and perceive Cannabis. From all of us in our industry, our hats are off to Sports Illustrated for their reporting.”
Scientific research studies have found that CBD reduces brain swelling and neurological impairment following an impact brain injury, which in turn improves recovery. Kannalife currently holds two licenses with the National Institutes of Health for U.S. Patent 6,630,507 “Cannabinoids as Antioxidants and Neuroprotectants.” These licenses are currently in use by Kannalife to develop novel therapeutic drugs to treat chronic traumatic encephalopathy (CTE) and hepatic encephalopathy (HE). While CBD from marijuana is tightly restricted, CBD found naturally in hemp is legal throughout all 50 states in the U.S.
About Kannalife Sciences, Inc.
Kannalife Sciences, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy (“HE”) and Chronic Traumatic Encephalopathy (“CTE”). HE and CTE are oxidative stress related diseases that affect cognitive and behavioral functions. For more information, visit: www.Kannalife.com.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
Public Relations Contact:
Chief Executive Officer
Corporate Business Contact:
Nicholas R. Massalas
Director of Business Development
Medical Marijuana, Inc.
OTC Symbol: MJNA
Toll Free: 888-OTC-MJNA (888-682-6562)
Investor Relations Contact:
Toll Free: (877) 964.6463
Office/Direct: (858) 264-6500